During the peak of the COVID-19 pandemic, a collaborative team comprising Hopital Foch's respiratory disease department and the University Paris Saclay / UVSQ medicine faculty undertook a mission to develop a diagnostics solution possessing high-throughput capabilities, able to address massive populations in limited time-frames. In order to conceive this large-scale screening device, a particular focus on speed and non-invasiveness was required.

​

Following extensive R&D efforts, the team successfully developed a revolutionary method for diagnosing COVID-19 in under 1 minute, with a high level of accuracy, using nothing more than a simple exhaled breath. In 2022, the team was officially awarded recognition for their breakthrough innovation in the form of an international patent.

​

In the years that followed, the team dedicated their efforts to enhancing their technology and expanding its applications, with the objective of spreading the benefits of real-time breath analysis to a broader range of diseases and applications. In 2024, the team officially spun off from Hopital Foch and UVSQ to advance their services under the name of exhalon.io.